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MAINTAINED DURING 3 YEARS OF GROWTH
HORMONE (GH) SUBSTITUTION IN
HYPOPITUITARY ADULTS WITH GH
DEFICIENCY
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Svensson J1,Wirén L1, Götherström G1, Bengtsson BÅ1
1Research Centre for Endocrinology and Metabolism,
Sahlgrenska University Hospital, Göteborg, Sweden;
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OBJECTIVES: To investigate whether the improved well-
being and quality of life (QoL) and decreased use of
healthcare resources seen during the ﬁrst year of GH sub-
stitution therapy in GH-deﬁcient adults are maintained
over subsequent years of treatment.
METHODS: Data were analysed from 237 Swedish
hypopituitary adults with GH deﬁciency (GHD) who had
received 2 (n = 196) or 3 (n = 130) years of GH replace-
ment therapy (mean dose, 0.43mg/day). All patients (117
men, 120 women; mean age at baseline, 51.5 years; range,
35–69 years; 141 (60%) with at least three additional
hormone deﬁciencies, and 16 with isolated GHD) were
included in KIMS (Pharmacia International Metabolic
Database)—a pharmacoepidemiological survey of adults
with GHD. None had previously received GH replace-
ment in childhood. Eighty-ﬁve (36%) had had <10 years
of formal education; 142 (60%) were in full or part-
time work, and 39 (17%) had taken early retirement or
were receiving a disability pension. QoL was assessed
using AGHDA—a disease-speciﬁc questionnaire—and
the generic PGWB index. Information on the patients’
social situation and well-being was obtained from a
patient life situation form. Statistical analysis was by
repeated measurements regression.
RESULTS: A signiﬁcant subjective improvement in well-
being was noted by 78% of patients after 1 year and by
86% after 3 years. QoL (both AGHDA and PGWB)
showed statistically signiﬁcant improvements after 1 
year, which were sustained for up to 3 years. The VAS
score for leisure-time activity also increased signiﬁcantly
during the whole follow-up period, as did patients’ satis-
faction with their level of physical activity. Use of health-
care resources (days of reported sick-leave and doctor
visits) decreased signiﬁcantly during the ﬁrst year of 
treatment.
CONCLUSIONS: Three years of GH treatment in adults
with GHD has a sustained positive effect on well-being,
QoL and physical activity, and decreases the consumption
of healthcare resources.
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A RANDOMIZED, OPEN-LABEL PREFERENCE
STUDY OF GENGRAF® COMPARED TO
NEORAL® IN STABLE SOLID-ORGAN
TRANSPLANT RECIPIENTS
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Studies in healthy volunteers and renal transplant 
recipients indicated that Gengraf (Abbott: cyclosporine
capsule, USP Modiﬁed), had less negative attributes than
Neoral (cyclosporine capsule, USP Modiﬁed). Prior
research indicated patient dissatisfaction with smell, odor,
taste and size of CsA capsules.
OBJECTIVE: The objective of the PREFER Study was 
to evaluate CsA capsule preference using a validated CsA
Capsule Satisfaction Survey (CCSS) that measured the
impact of CsA’s attributes: odor, swallowability, taste,
breath and body odor on patient satisfaction.
METHOD: 1932 stable, solid-organ transplant recipients
(294 heart; 1420 kidney; 154 liver; 64 other) taking
stable doses of Neoral were randomized to Gengraf or
Neoral, (9 :1) on day 1. Subjects completed a pre-
randomization, day 1, baseline CCSS and day 28, Final
CCSS.
RESULTS: Subjects switched to Gengraf showed statisti-
cally signiﬁcant improvement of the six CsA Capsule
attributes and expressed preference for Gengraf over
Neoral. P-values for satisfaction of subjects switched to
Gengraf from Neoral were <0.001 in each of the attrib-
utes of capsule odor, swallowability, taste, halitosis, body
odor, and overall score. Final preference outcomes of the
CCSS showed the preference for Gengraf over Neoral 
in the attributes studied as follows (equal preferences 
not shown): 66.3% versus 7% for capsule odor, 51.5%
versus 6.7% for swallowability, 57.1% versus 6.5% for
taste, 52.5% versus 5.8% for associated halitosis, and
48.4% versus 5.3% for associated body odor. Based on
overall experience, 61.9% preferred Gengraf and 13.7%
preferred Neoral.
CONCLUSION: In conclusion, in this study, when com-
paring CsA attributes of odor, ease of swallowing, taste,
halitosis, and body odor, transplant patients prefer
Gengraf to Neoral. Further evaluation is necessary to
determine the impact on long-term compliance.
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OBJECTIVES: The purpose of this project was to prepare
and test culturally and linguistically appropriate versions
of the SF-36v.2 in Crow and Salish. Prior translation
efforts (e.g., IQOLA) have shown that cultural as well 
as linguistic considerations must be made when creating
culturally-appropriate versions of the MOS SF-36 
Health Status Survey (SF-36). The populations selected
for this project were two Native American populations 
in Montana who are interested in preserving their native
languages.
METHODS: Representatives of the Confederated Salish
Kootenai Tribes (CSKT) expressed a preference for an
English version of the SF-36; this was based on the need
to preserve a pure form of the native language. Repre-
sentatives of the Crow Tribe eventually decided to not
participate in the study. In spring 2001, four hundred
adult members of the CSKT were randomly selected to
receive a mailed copy of the SF-36v.2 (English) along with
a questionnaire (e.g., demographic, co-morbidity, and
health care encounters), a cover letter, and a ﬁve-dollar
incentive.
RESULTS: Response rate was 51% (205/400). Item-to-
scale correlations ranged from -0.0166 (Pain) to +0.932
(Role-Emotional) with most in the 0.7 to 0.8 range. Scale-
to-General Health Scale correlations were all positive,
ranging from 0.2611 (Pain) to 0.5986 (Mental Health).
The Pain Scale (Items 7 and 8) had the poorest item-to-
scale and scale-to-General Health Scale correlations. The
transformed norm-based z-scores for the CSKT popula-
tion ranged from 38.1688 (Pain) to 48.1198 (Vitality).
CONCLUSIONS: While Native Americans may be inter-
ested in preserving and promoting the use of their native
languages, they may not be interested in doing so in
health surveys. The performance of all scales but the Pain
Scale in the CSKT population appears to be good;
however, further investigation into the Pain Scale results
is needed. It is also important to recognize that other
tribes may have different norms and response issues.
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PREVENTABLE DRUG-RELATED MORBIDITY IN
OLDER ADULTS IN NOVA SCOTIA, CANADA:
DEVELOPMENT OF QUALITY INDICATORS
Robertson H, MacKinnon NJ,Tonks RS
Dalhousie University, Halifax, NS, Canada
The role of quality measurement of medication use is
becoming more critical as consumers, employers and
others demand increased accountability and transparency
from the delivery of health care. At this time, however,
there are no explicit quality indicators of preventable
drug-related morbidity (PDRM) that could be used by
clinicians and/or a health care organization.
OBJECTIVES: To create consensus-approved clinical
indicators of PDRM in older adults applicable to the
Canadian health care system.
METHODS: A written survey was constructed, listing the
clinical outcome and pattern of care related to a number
of possible PDRMs in older adults. Using the Delphi 
technique, two independent six-member expert panels
(geriatricians, clinical pharmacologists) in Nova Scotia,
Canada were asked to judge whether the outcome in each
situation was foreseeable and recognizable, and whether
causality was identiﬁable and controllable. The panel
could also suggest additional PDRMs. Subsequently, a
focus group of 12 general practitioners (GPs) evaluated
these PDRM indicators. The inclusion of this third panel
provided a triangulation of expert opinion across three
practice areas.
RESULTS: The two expert panels proposed 58 indicators
of PDRMs in older adults after two rounds of the Delphi
technique. The GPs agreed with 52 (90%) of these PDRM
indicators.
CONCLUSIONS: This study showed that consensus on
quality indicators of PDRM can be reached among
experts. These indicators could be used by a health care
organization to proactively identify patients at risk for a
PDRM and to improve the quality, safety and appropri-
ateness of medication use. Additionally, the indicators
form an important bridge between processes and out-
comes of care and could be used in conjunction with
existing medication use quality indicators. Subsequent
phases of this study will involve pharmacist validation of
these PDRMs, and identiﬁcation (through an integrated
medical database of older Nova Scotians) of patients who
experienced PDRMs.
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CONTENT ANALYSIS OF QUALITY OF LIFE
AND PHARMACOECONOMIC MESSAGES IN
PHARMACEUTICAL PRODUCT
ADVERTISEMENTS
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Medical journal advertisements have been evaluated for
pharmacoeconomic and quality of life (QoL) content,
however no studies have compared advertisements from
general health care (General) and managed care (MC)
journals.
OBJECTIVES: The speciﬁc objectives of this study were
to: 1) determine the number of pharmacoeconomic and
QoL messages encountered in General and MC journals;
and 2) evaluate the frequency of advertisements with
respect to the type and content of pharmacoeconomic or
QoL messages.
METHODS: The study was a review of all advertisements
in six journals appearing from July 1999–June 2001.
Journals were divided into two categories: General and
MC. Three independent reviewers evaluated the content
of each advertisement, and designated advertisements as
those containing QoL, implicit or explicit, and/or phar-
macoeconomic messages. Advertisements were also 
evaluated based on their use of supporting evidence 
for these messages. Advertisements in General and MC
